Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Mikhael

Showing results (91-100 of 104) with videos related to

Pageof 11
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 27, 2020
The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease StudyAndrew J Cowan, Helen Baldomero, Yoshiko Atsuta, et al.
Blood|October 23, 2013
Smoldering multiple myeloma requiring treatment: time for a new definition?Angela Dispenzieri, A Keith Stewart, Asher Chanan-Khan, et al.
Blood Cancer Journal|August 1, 2018
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myelomaShaji K Kumar, Francis K Buadi, Betsy LaPlant, et al.
Blood|October 6, 2016
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomibShaji K Kumar, Betsy R LaPlant, Craig B Reeder, et al.
The Lancet. Oncology|May 31, 2024
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy CommitteeYi Lin, Lugui Qiu, Saad Usmani, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 7, 2016
Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR AnalysisEmma C Scott, Parameswaran Hari, Manish Sharma, et al.
The Lancet. Oncology|July 6, 2023
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working GroupMeletios A Dimopoulos, Giampaolo Merlini, Frank Bridoux, et al.
The Lancet. Haematology|March 28, 2022
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort studyHabib El-Khoury, David J Lee, Jean-Baptiste Alberge, et al.
Leukemia|January 27, 2025
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myelomaLuciano J Costa, Rahul Banerjee, Hira Mian, et al.
The Lancet. Oncology|May 2, 2024
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myelomaPaula Rodriguez-Otero, Saad Usmani, Adam D Cohen, et al.
Pageof 11

Showing results (91-100 of 104) with videos related to

Sort By:
Pageof 11
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 27, 2020
The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease StudyAndrew J Cowan, Helen Baldomero, Yoshiko Atsuta, et al.
Blood|October 23, 2013
Smoldering multiple myeloma requiring treatment: time for a new definition?Angela Dispenzieri, A Keith Stewart, Asher Chanan-Khan, et al.
Blood Cancer Journal|August 1, 2018
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myelomaShaji K Kumar, Francis K Buadi, Betsy LaPlant, et al.
Blood|October 6, 2016
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomibShaji K Kumar, Betsy R LaPlant, Craig B Reeder, et al.
The Lancet. Oncology|May 31, 2024
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy CommitteeYi Lin, Lugui Qiu, Saad Usmani, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 7, 2016
Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR AnalysisEmma C Scott, Parameswaran Hari, Manish Sharma, et al.
The Lancet. Oncology|July 6, 2023
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working GroupMeletios A Dimopoulos, Giampaolo Merlini, Frank Bridoux, et al.
The Lancet. Haematology|March 28, 2022
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort studyHabib El-Khoury, David J Lee, Jean-Baptiste Alberge, et al.
Leukemia|January 27, 2025
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myelomaLuciano J Costa, Rahul Banerjee, Hira Mian, et al.
The Lancet. Oncology|May 2, 2024
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myelomaPaula Rodriguez-Otero, Saad Usmani, Adam D Cohen, et al.
Pageof 11